AEQ Stock Overview
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Aequus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.053 |
| 52 Week Low | CA$0.0005 |
| Beta | 0.29 |
| 1 Month Change | -87.50% |
| 3 Month Change | -93.33% |
| 1 Year Change | -95.00% |
| 3 Year Change | -99.59% |
| 5 Year Change | -99.55% |
| Change since IPO | -99.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| AEQ | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.5% |
| 1Y | -95.0% | -28.6% | 1.3% |
Return vs Industry: AEQ underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: AEQ underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| AEQ volatility | |
|---|---|
| AEQ Average Weekly Movement | 217.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AEQ's share price has been volatile over the past 3 months.
Volatility Over Time: AEQ's weekly volatility has increased from 121% to 218% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 12 | Doug Janzen | www.aequuspharma.ca |
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Aequus Pharmaceuticals Inc. Fundamentals Summary
| AEQ fundamental statistics | |
|---|---|
| Market cap | €1.36m |
| Earnings (TTM) | -€2.23m |
| Revenue (TTM) | €400.57k |
3.4x
P/S Ratio-0.6x
P/E RatioIs AEQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AEQ income statement (TTM) | |
|---|---|
| Revenue | CA$587.09k |
| Cost of Revenue | CA$152.43k |
| Gross Profit | CA$434.66k |
| Other Expenses | CA$3.70m |
| Earnings | -CA$3.27m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 74.04% |
| Net Profit Margin | -556.88% |
| Debt/Equity Ratio | -94.0% |
How did AEQ perform over the long term?
See historical performance and comparison